Multiple Sclerosis Research Today is a free monthly online journal that collates and summarizes the latest research about Multiple Sclerosis, including details on diagnosis, symptoms, treatment, prognosis.

Volume 7 (2010), Issue 12 (December)

1. Leptin modulates the survival of autoreactive CD4+ T cells through the nutrient/energy-sensing mammalian target of rapamycin signaling pathway.
   J Immunol, 185(12): 7474-9. [Abstract] [Full-text]
2. Oligodendrocyte-specific FADD deletion protects mice from autoimmune-mediated demyelination.
   J Immunol, 185(12): 7646-53. [Abstract] [Full-text]
3. Leptin modulates the survival of autoreactive CD4+ T cells through the nutrient/energy-sensing mammalian target of rapamycin signaling pathway.
   J Immunol, 185(12): 7474-9. [Abstract] [Full-text]
4. Oligodendrocyte-specific FADD deletion protects mice from autoimmune-mediated demyelination.
   J Immunol, 185(12): 7646-53. [Abstract] [Full-text]
5. The contribution of MRI in assessing cognitive impairment in multiple sclerosis.
   Neurology, 75(23): 2121-8. [Abstract] [Full-text]
6. Absence of cortical demyelination in neuromyelitis optica.
   Neurology, 75(23): 2103-9. [Abstract] [Full-text]
7. Neurocognitive sequelae in African American and Caucasian children with multiple sclerosis.
   Neurology, 75(23): 2097-102. [Abstract] [Full-text]
8. Distinct properties of circulating CD8+ T cells in FTY720-treated patients with multiple sclerosis.
   Arch Neurol, 67(12): 1449-55. [Abstract] [Full-text]
9. Incidental MRI lesions suggestive of multiple sclerosis in asymptomatic patients in Karachi, Pakistan.
   J Neurol Neurosurg Psychiatry, 82(1): 83-5. [Abstract] [Full-text]
10. How long can you keep working with benign multiple sclerosis?
    J Neurol Neurosurg Psychiatry, 82(1): 78-82. [Abstract] [Full-text]
11. T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry, 82(1): 72-7. [Abstract] [Full-text]
12. Incidental MRI lesions suggestive of multiple sclerosis in asymptomatic patients in Karachi, Pakistan.
    J Neurol Neurosurg Psychiatry, 82(1): 83-5. [Abstract] [Full-text]
13. How long can you keep working with benign multiple sclerosis?
    J Neurol Neurosurg Psychiatry, 82(1): 78-82. [Abstract] [Full-text]
14. T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis.
    J Neurol Neurosurg Psychiatry, 82(1): 72-7. [Abstract] [Full-text]
15. Regional homogeneity changes in patients with neuromyelitis optica revealed by resting-state functional MRI.
    Clin Neurophysiol, 122(1): 121-7. [Abstract] [Full-text]
16. Cells of the oligodendroglial lineage, myelination, and remyelination.
    Biochim Biophys Acta, 1812(2): 184-93. [Abstract] [Full-text]
17. Human endogenous retroviruses and multiple sclerosis: innocent bystanders or disease determinants?
    Biochim Biophys Acta, 1812(2): 162-76. [Abstract] [Full-text]
18. The blood-brain barrier, chemokines and multiple sclerosis.
    Biochim Biophys Acta, 1812(2): 220-30. [Abstract] [Full-text]
19. Assessment of evidence for a protective role of vitamin D in multiple sclerosis.
    Biochim Biophys Acta, 1812(2): 202-12. [Abstract] [Full-text]
20. MS and the B cell controversy.
    Biochim Biophys Acta, 1812(2): 231-8. [Abstract] [Full-text]
21. Inflammation, demyelination, and degeneration - recent insights from MS pathology.
    Biochim Biophys Acta, 1812(2): 275-82. [Abstract] [Full-text]
22. Contribution of CD8 T lymphocytes to the immuno-pathogenesis of multiple sclerosis and its animal models.
    Biochim Biophys Acta, 1812(2): 151-61. [Abstract] [Full-text]
23. The role of antigen presenting cells in multiple sclerosis.
    Biochim Biophys Acta, 1812(2): 265-74. [Abstract] [Full-text]
24. Disruption of central nervous system barriers in multiple sclerosis.
    Biochim Biophys Acta, 1812(2): 252-64. [Abstract] [Full-text]
25. Th1 versus Th17: are T cell cytokines relevant in multiple sclerosis?
    Biochim Biophys Acta, 1812(2): 246-51. [Abstract] [Full-text]
26. The role of antibodies in multiple sclerosis.
    Biochim Biophys Acta, 1812(2): 239-45. [Abstract] [Full-text]
27. Mouse models for multiple sclerosis: historical facts and future implications.
    Biochim Biophys Acta, 1812(2): 177-83. [Abstract] [Full-text]
28. Radical changes in multiple sclerosis pathogenesis.
    Biochim Biophys Acta, 1812(2): 141-50. [Abstract] [Full-text]
29. Viral triggers of multiple sclerosis.
    Biochim Biophys Acta, 1812(2): 132-40. [Abstract] [Full-text]

© 2004-2012 Multiple Sclerosis Research Today. All Rights Reserved.